Source: Reuters (via feed)
Shares of MiniMed, the diabetes business spun off from Medtronic, fell 4.8% below their offer price in their Nasdaq debut on Friday. The opening share price valued MiniMed at approximately $5.3 billion. Medtronic is a major medical device maker, and MiniMed focuses on diabetes technology. The unit’s public listing marks its first day as an independent company on the stock exchange. Despite the initial decrease in share price, the IPO values the diabetes-related unit at over $5 billion. This follows a broader trend of medical device companies spin-offs aiming for more focused growth. Analysts will watch for MiniMed’s market performance in the coming sessions. The move may affect investor interest in diabetes technology and related health care sectors.
MiniMed’s valuation provides a benchmark for diabetes technology sector growth prospects. It also reflects investor appetite for focused medical device firms.
